Compare COVID-19 Oral Antivirals
February 2022
You'll be asked about the new COVID-19 oral antivirals nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.
Eligibility. Educate that these meds are for outpatients with a positive COVID-19 test who are at high risk of developing severe illness (diabetes, etc)...regardless of vaccination status.
Nirmatrelvir/ritonavir is for age 12 and up...molnupiravir is for 18 and up. Either is started within 5 days of symptoms...and used bid for 5 days. Patients don't currently have to pay for them.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote